View Older Stories View More Recent Stories

Nov 1, 2016 04:05PM Novocure Recognizes National Family Caregivers Month by Supporting GBM Heroes Event
Oct 12, 2016 07:01AM Novocure (NVCR) Announces Enrollment of First Patient in METIS Trial
Oct 12, 2016 07:00AM Novocure Enrolls First Patient in Phase 3 Pivotal Brain Metastases Trial
Sep 30, 2016 12:39PM CORRECTING and REPLACING – Novocure to Report Third Quarter 2016 Financial Results
Sep 30, 2016 07:30AM Novocure to Report Third Quarter 2016 Financial Results
Sep 19, 2016 07:30AM CNS Oncology Publishes Tumor Treating Fields Treatment Planning and Patient Follow-up Guidelines in Glioblastoma
Sep 15, 2016 07:30AM Novocure’s Executive Chairman William Doyle to Present on Tumor Treating Fields at New York Academy of Sciences’ Symposium on Bioelectronic Medicine
Sep 14, 2016 08:00AM Two Institutions Publish Independent Data on Novocure’s Tumor Treating Fields
Sep 12, 2016 07:08AM Novocure (NVCR) Announces Significant Data from Optune Combo Phase 3 in GBM
Sep 12, 2016 07:00AM Long-term Analysis of All 695 Patients Enrolled in Novocure’s Phase 3 Pivotal Trial in Newly Diagnosed Glioblastoma Confirms Superior Progression Free and Overall Survival Seen in the Trial’s Inte
Sep 1, 2016 07:00AM International Journal of Cancer Publishes Data Showing Tumor Treating Fields in Combination with Paclitaxel is Therapeutically Effective against Ovarian Cancer Cells in Vitro and in Vivo
Aug 16, 2016 07:09AM Novocure (NVCR) Offers Positive Case Study on Second-Gen Optune System
Aug 16, 2016 07:00AM Novocure Converts More Than 500 U.S. Patients to Second Generation Optune within Four Weeks of FDA Approval on July 13
Aug 8, 2016 04:05PM Novocure to Present at Upcoming Investor Conferences
Jul 28, 2016 06:30AM Novocure Reports Second Quarter 2016 Financial Results and Provides Company Update
Jul 28, 2016 06:25AM Novocure to Host Research and Development Day on Dec. 12, 2016
Jul 26, 2016 07:23AM Novocure (NVCR) Announces NCCN Recommendation of Optune as Standard GBM Treatment Option
Jul 26, 2016 07:01AM NCCN Guidelines Recommend Optune as a Standard Treatment Option for Newly Diagnosed Glioblastoma
Jul 13, 2016 04:00PM Novocure (NVCR) Second Generation Optune System Approved by FDA
Jul 13, 2016 04:00PM Novocure Receives FDA Approval for Second Generation Optune System
Jun 30, 2016 04:00PM Novocure Announces $75 Million Drawdown under Its Term Loan Agreement through Pharmakon Advisors
Jun 30, 2016 07:00AM Novocure to Report Second Quarter 2016 Financial Results
Jun 8, 2016 07:00AM Novocure to Present at JMP Securities 2016 Life Sciences Conference
May 31, 2016 07:45AM Novocure (NVCR) Announces FDA Approval of IDE to Initiate METIS Trial
May 31, 2016 07:30AM Novocure Receives IDE Approval to Initiate METIS Trial
May 23, 2016 07:34AM Novocure (NVCR) Enrolls Final Patient in TTFields + Chemotherapy Phase 2
May 23, 2016 07:30AM Novocure Enrolls Last Patient in PANOVA Trial of Tumor Treating Fields Plus Chemotherapy in Advanced Pancreatic Cancer
May 19, 2016 04:34PM Novocure (NVCR) Completes Enrollment in INNOVATE Trial
May 19, 2016 04:30PM Novocure Enrolls Last Patient in INNOVATE Trial Testing Tumor Treating Fields Plus Paclitaxel in Recurrent Ovarian Cancer
May 18, 2016 05:03PM Novocure (NVCR) Says New Subgroup Analysis of Ongoing Phase 2 Pilot PANOVA Trial to be Presented at ASCO
May 18, 2016 05:00PM Novocure Announces Presentation of Subgroup Analysis of PANOVA Data Showing Overall Survival Benefit of Tumor Treating Fields Plus Gemcitabine in Advanced Pancreatic Cancer Patients
May 13, 2016 07:30AM Novocure to Present New Preclinical Data Showing Additive Efficacy of Tumor Treating Fields and PD-1 Inhibitors at the American Association of Immunologists’ Annual Meeting 2016
May 11, 2016 04:05PM Novocure Enters into Employment Agreement with William Doyle
May 9, 2016 04:00PM Novocure Reports First Quarter 2016 Financial Results and Provides Company Update
May 6, 2016 07:35AM Novocure Kicks Off Brain Tumor Awareness Month with New Activities to Support and Inspire Those Affected by Glioblastoma
May 5, 2016 07:35AM Novocure (NVCR) Names New GBM Learning Resource Available
May 5, 2016 07:30AM Novocure Delivers New Informational Resource for Glioblastoma Brain Cancer
May 4, 2016 07:30AM Blue Cross Blue Shield of Michigan Issues Positive Coverage Decision for Optune
Apr 26, 2016 07:53AM Novocure (NVCR) Updates on Expansion of Optune Availability
Apr 26, 2016 07:30AM Novocure’s Optune Now Available at More Than 360 Cancer Treatment Centers in the U.S.
Apr 25, 2016 07:32AM Novocure (NVCR) Says RTOG Foundation to Coducxt Phase 2 Pilot Trial Testing of Optune/Bevacizumab
Apr 25, 2016 07:30AM FDA Approves Investigational Device Exemption for RTOG Trial of Novocure’s Optune together with Bevacizumab for Patients with Bevacizumab-Refractory Recurrent Glioblastoma
Apr 7, 2016 07:55AM Novocure (NVCR) to Present Three Preclinical Abstracts on Tumor Treating Fields at AACR
Apr 7, 2016 07:30AM Novocure to Present New Preclinical Data on Tumor Treating Fields at American Association for Cancer Research Annual Meeting 2016
Apr 5, 2016 07:30AM Novocure to Report First Quarter 2016 Financial Results
Mar 30, 2016 07:30AM Novocure and Leading Cancer Center Enter a Preclinical Research Collaboration to Study Tumor Treating Fields
Mar 9, 2016 07:00AM Red Journal Publishes Data Supporting Personalized Treatment Planning to Increase TTFields Efficacy for Patients with Glioblastoma
Mar 3, 2016 07:36AM Novocure (NVCR) Announces Positive Optune Coverage Decision from Humana (HUM)
Mar 3, 2016 07:30AM Humana Issues Positive Coverage Decision For Optune
Feb 29, 2016 04:24PM Novocure Reports 2015 Operating Statistics and Financial Results
View More Recent Stories View Older Stories